Lipocine receives updated regulatory guidance on lpcn 1154

Salt lake city , feb. 6, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for lpcn 1154 which the company is developing for postpartum depression (ppd) treatment.  as previously disclosed, the company was scheduled to meet with the u.s. food and drug administration (fda or the division) in q1 2025 to discuss the nda submission package of lpcn 1154.
LPCN Ratings Summary
LPCN Quant Ranking